Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Table 2 Changes from baseline in lung function and body plethysmography parameters at Week 3 (ITT population)

Parameter	Placebo (N = 108)	Aclidinium 400 μg BID (N = 109)	Treatment difference vs placebo (95% CI)
Pre-dose (trough) IC (mL)	20 (25)	98 (24)	78 (10, 145)^*
Pre-dose (trough) FEV₁ (mL)	-25 (21)	108 (21)	132 (74, 191)^****
Pre-dose (trough) FVC (mL)	-46 (31)	198 (30)	243 (157, 329)^****
FRC (mL)
Pre-dose (trough)	15 (39)	-182 (39)	-197 (-321, -72)^**
Post-dose	-130 (46)	-449 (46)	-318 (-448, -189)^****
RV (mL)
Pre-dose (trough)	15 (60)	-222 (60)	-238 (-396, -79)^**
Post-dose	-81 (57)	-523 (57)	-443 (-599, -286)^****
TLC (mL)
Pre-dose (trough)	-6 (41)	-82 (41)	-76 (-201, 49)
Post-dose	-49 (41)	-199 (41)	-150 (-262, -37)^**
sGaw (s^-1kPa^-1)
Pre-dose (trough)	0.002 (0.020)	0.096 (0.020)	0.094 (0.038, 0.150)^**
Post-dose	0.054 (0.027)	0.297 (0.026)	0.243 (0.182, 0.303)^****

Data reported as least squares means (standard error) change from baseline (analysis of covariance).
^*p < 0.05, ^**p < 0.01, ^****p < 0.0001 versus placebo.
BID, twice daily; CI, confidence interval; FEV₁, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; ITT, intent-to-treat; RV, residual volume; sGaw, specific airway conductance; TLC, total lung capacity.

ISSN: 1471-2466